P21

Typical use cases

Dosing guidelines

Titration

Typically flat-dosed in the research protocols that exist; no validated titration scheme.

Reconstitution

A 5 mg vial is commonly reconstituted with ~1–2 mL bacteriostatic water for subcutaneous research use; note the compound was engineered for oral activity in animal studies.

Injection sites

Subcutaneous (abdomen/flank) in typical research protocols; oral administration is the route used in much of the animal literature.

Storage & handling

Lyophilized: stable months cool/dark, longer frozen. Reconstituted: refrigerate (2–8 °C).

Side effects

• Injection-site reaction (subcutaneous) Mild · Uncommon
• Human side-effect profile unknown (no clinical data) Moderate · Rare

Research summary

P021 is a small peptidomimetic derived from an active region of ciliary neurotrophic factor (CNTF), built on an Ac-DGGL core with an adamantane modification to improve stability and blood-brain-barrier penetration; it is reported to enhance dentate-gyrus neurogenesis and BDNF expression, partly via inhibition of leukemia inhibitory factor signaling, while avoiding the toxicity of native CNTF. In transgenic Alzheimer's mouse models it has been associated with reduced tau hyperphosphorylation, lower soluble Aβ, and improved memory. The key caveat is that essentially the entire evidence base comes from preclinical rodent models with no human clinical trials, so efficacy and safety in people are unknown. Educational only — not medical advice.

Key references

• Chohan et al., Neurobiol. Aging (2011) — peptidergic compound P021 enhances neurogenesis and cognition
• Kazim et al., J. Neurosci. (2014) — P021 prevents synaptic deficits and cognitive impairment in 3xTg-AD mice

Related compounds